Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.

IF 7.7 2区 医学 Q1 ONCOLOGY
Cancer and Metastasis Reviews Pub Date : 2024-12-01 Epub Date: 2024-07-26 DOI:10.1007/s10555-024-10202-w
Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal
{"title":"Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.","authors":"Chelsi James, Akeem Whitehead, Jasmine T Plummer, Rory Thompson, Simone Badal","doi":"10.1007/s10555-024-10202-w","DOIUrl":null,"url":null,"abstract":"<p><p>Developing anticancer drugs from preclinical to clinical takes approximately a decade in a cutting-edge biomedical lab and still 97% of most fail at clinical trials. Cell line usage is critical in expediting the advancement of anticancer therapies. Yet developing appropriate cell lines has been challenging and overcoming these obstacles whilst implementing a systematic approach of utilizing 3D models that recapitulate the tumour microenvironment is prudent. Using a robust and continuous supply of cell lines representing all ethnic groups from all locales is necessary to capture the evolving tumour landscape in culture. Next, the conversion of these models to systems on a chip that can by way of high throughput cytotoxic assays identify drug leads for clinical trials should fast-track drug development while markedly improving success rates. In this review, we describe the challenges that have hindered the progression of cell line models over seven decades and methods to overcome this. We outline the gaps in breast and prostate cancer cell line pathology and racial representation alongside their involvement in relevant drug development.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":" ","pages":"1529-1548"},"PeriodicalIF":7.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and Metastasis Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10555-024-10202-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Developing anticancer drugs from preclinical to clinical takes approximately a decade in a cutting-edge biomedical lab and still 97% of most fail at clinical trials. Cell line usage is critical in expediting the advancement of anticancer therapies. Yet developing appropriate cell lines has been challenging and overcoming these obstacles whilst implementing a systematic approach of utilizing 3D models that recapitulate the tumour microenvironment is prudent. Using a robust and continuous supply of cell lines representing all ethnic groups from all locales is necessary to capture the evolving tumour landscape in culture. Next, the conversion of these models to systems on a chip that can by way of high throughput cytotoxic assays identify drug leads for clinical trials should fast-track drug development while markedly improving success rates. In this review, we describe the challenges that have hindered the progression of cell line models over seven decades and methods to overcome this. We outline the gaps in breast and prostate cancer cell line pathology and racial representation alongside their involvement in relevant drug development.

Abstract Image

进展失败:开发靶向疗法的乳腺癌和前列腺癌细胞系。
在尖端生物医学实验室中,抗癌药物从临床前研究到临床开发大约需要十年时间,而大多数药物在临床试验中仍有 97% 以失败告终。细胞系的使用对于加快抗癌疗法的进展至关重要。然而,开发合适的细胞系一直是个挑战,在克服这些障碍的同时,利用三维模型再现肿瘤微环境的系统方法是非常谨慎的。要想在培养过程中捕捉到不断变化的肿瘤情况,就必须使用代表所有地区所有种族群体的强大而持续的细胞系供应。接下来,将这些模型转化为芯片上的系统,通过高通量细胞毒性检测确定用于临床试验的药物先导物,应能快速推进药物开发,同时显著提高成功率。在这篇综述中,我们介绍了七十年来阻碍细胞系模型发展的挑战以及克服这些挑战的方法。我们概述了乳腺癌和前列腺癌细胞系病理学和种族代表性方面的差距,以及它们参与相关药物开发的情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
17.00
自引率
0.00%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms.The transformation of biology from a largely descriptive, phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments. A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease, as well as to highlight new and promising directions, be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信